--- title: "Selank vs Semax | PepTracker Pro" url: https://peptrackerpro.com/compare/selank-vs-semax description: "Selank and Semax are both Russian-developed neuropeptides, but Selank is primarily studied for anxiety modulation while Semax is studied for cognitive enhancement and neuroprotection." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This comparison is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Selank vs Semax Last updated: 2026-06-22 - Selank is derived from the immunomodulatory peptide tuftsin; Semax is derived from ACTH (adrenocorticotropic hormone). - Selank research focuses on anxiolytic and immune-modulatory effects; Semax research emphasizes cognitive enhancement and neuroprotection. - Both were developed at the Institute of Molecular Genetics in Russia and have regulatory approval there as nasal sprays. - Selank modulates GABA and serotonin systems; Semax primarily influences BDNF and melanocortin pathways. - Both have relatively favorable safety profiles in available studies. Selank and Semax are both Russian-developed neuropeptides, but Selank is primarily studied for anxiety modulation while Semax is studied for cognitive enhancement and neuroprotection. ## Side-by-Side Comparison | Attribute | Selank | Semax | | --- | --- | --- | | What It Is | A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. | A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. | | Typical Research Focus | Anxiety ReliefMoodCognitionNeuroprotectionImmune Support | CognitionNeuroprotectionMoodRecovery | | Proposed Mechanisms | Not yet documented | Not yet documented | | Evidence Snapshot | Medium Evidence prescription drug | Medium Evidence prescription drug | | Cautions | - Approved in Russia but not FDA-approved in the US - Most research published in Russian-language journals - Long-term Western clinical data limited | - Approved in Russia/Ukraine but not FDA-approved - PCAC review scheduled July 24, 2026 for potential 503A Bulks List addition; proposed indications include cerebral ischemia, migraine, and trigeminal neuralgia - Western clinical trial data is limited | ### Selank What It Is A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. Research Focus Anxiety ReliefMoodCognitionNeuroprotectionImmune Support Evidence Medium Evidence Cautions - Approved in Russia but not FDA-approved in the US - Most research published in Russian-language journals - Long-term Western clinical data limited ### Semax What It Is A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. Research Focus CognitionNeuroprotectionMoodRecovery Evidence Medium Evidence Cautions - Approved in Russia/Ukraine but not FDA-approved - PCAC review scheduled July 24, 2026 for potential 503A Bulks List addition; proposed indications include cerebral ischemia, migraine, and trigeminal neuralgia - Western clinical trial data is limited ## When Researchers Compare Them Selank and Semax are often compared because both originate from the same Russian research institution and are among the few peptides with regulatory approval (in Russia) for neurological applications. Despite this shared background, their mechanisms and primary research applications diverge. Selank, a synthetic analog of the immunopeptide tuftsin, has been studied for its effects on the GABAergic and serotonergic systems. Research has explored its potential anxiolytic properties and immune-modulatory effects without the sedation typically associated with benzodiazepines. Semax, derived from a fragment of ACTH (4-10), has been investigated for cognitive enhancement and neuroprotection. Studies suggest it may increase brain-derived neurotrophic factor (BDNF) levels and modulate melanocortin receptors. Research has examined its potential role in stroke recovery, cognitive decline, and attention disorders. ## Peptide Profiles Selank Profile: https://peptrackerpro.com/peptides/selank Semax Profile: https://peptrackerpro.com/peptides/semax ## Citations 1. [1] Uchakina ON. et al. — Immunomodulatory effects of selank. Bull Exp Biol Med. 2008 Source (https://pubmed.ncbi.nlm.nih.gov/) 2. [2] Addiction Recovery Peptides 2026 Update — RealPeptides Source (https://www.realpeptides.co/addiction-recovery-peptides-2026-update/) ### Explore Research Tools Use calculators for reconstitution, dosing references, and more. Use PepTracker Pro Tools (https://peptrackerpro.com/calculators) ## Related Peptides ### Cerebrolysin Medium Evidence A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions. Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Cognition: https://peptrackerpro.com/benefits/cognition Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/cerebrolysin \+ Compare: https://peptrackerpro.com/compare?select=cerebrolysin Track in App: https://app.peptrackerpro.com/?add=cerebrolysin ### Davunetide Low Evidence An eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/davunetide \+ Compare: https://peptrackerpro.com/compare?select=davunetide Track in App: https://app.peptrackerpro.com/?add=davunetide ### Dihexa Low Evidence A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/dihexa \+ Compare: https://peptrackerpro.com/compare?select=dihexa Track in App: https://app.peptrackerpro.com/?add=dihexa ### DSIP Low Evidence A neuropeptide studied for its role in sleep regulation and stress modulation. Sleep: https://peptrackerpro.com/benefits/sleep Mood: https://peptrackerpro.com/benefits/mood Anxiety Relief: https://peptrackerpro.com/benefits/anxiety-relief Pain Relief: https://peptrackerpro.com/benefits/pain-relief View Details: https://peptrackerpro.com/peptides/dsip \+ Compare: https://peptrackerpro.com/compare?select=dsip Track in App: https://app.peptrackerpro.com/?add=dsip ### P21 Medium Evidence An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models. View Details: https://peptrackerpro.com/peptides/p21 \+ Compare: https://peptrackerpro.com/compare?select=p21 Track in App: https://app.peptrackerpro.com/?add=p21 ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. View Details: https://peptrackerpro.com/peptides/trontinemab \+ Compare: https://peptrackerpro.com/compare?select=trontinemab Track in App: https://app.peptrackerpro.com/?add=trontinemab ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Selank vs Semax", "description": "Selank and Semax are both Russian-developed neuropeptides, but Selank is primarily studied for anxiety modulation while Semax is studied for cognitive enhancement and neuroprotection.", "dateModified": "2026-06-22", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/compare/selank-vs-semax" } } ] ```